CAPR Stock Analysis: Capricor Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 1.299m USD | 12M Return: 124.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 35.1M
Qual. Beats: -2
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Capricor Therapeutics is a clinical-stage biotechnology company developing cell and exosome-based therapeutics, with a primary focus on Duchenne muscular dystrophy (DMD). Its lead candidate, Deramiocel (an allogeneic cardiosphere-derived cell therapy), is currently in Phase 3 clinical trials for DMD. The company is also advancing a pipeline of exosome-based vaccine and therapeutic programs, including candidates for SARS-CoV-2 and other diseases, most of which remain in preclinical or early Phase 1 stages.
The company was founded in 2005 and is headquartered in San Diego, California. It operates a research-and-development-driven business model, relying on license agreements with academic and research institutions-including Johns Hopkins University, the University of Rome, Cedars-Sinai Medical Center, and Life Technologies-to access foundational technologies for its cell and exosome platforms. As a clinical-stage biotech, Capricor has no products on the market, and its long-term value depends on successful clinical development, regulatory approval, and eventual commercialization or partnership-based monetization of its lead programs.
- Deramiocel Phase 3 HOPE-3 trial topline data readout expected
- FDA BLA acceptance decision for Deramiocel in DMD
- Sarepta Elevidys competition pressures DMD market opportunity
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.35 > 0.02 and ΔFCF/TA -4.25 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.28 > 3% & CFO -92.6m > Net Income -114.6m |
| Net Debt (-242.7m) to EBITDA (893.3m): -0.27 < 3 |
| Current Ratio: 8.42 > 1.5 & < 3 |
| Outstanding Shares: last quarter (57.4m) vs 12m ago 25.85% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 11.29%; Δ -11.29% > 0%) |
| Interest Coverage Ratio: -36.62 > 6 (EBIT TTM -111.5m / Interest Expense TTM 3.05m) |
| A: 0.76 (Total Current Assets 283.1m - Total Current Liabilities 33.6m) / Total Assets 326.3m |
| B: -1.04 (Retained Earnings -338.8m / Total Assets 326.3m) |
| C: -0.46 (EBIT TTM -111.5m / Avg Total Assets 240.0m) |
| D: 5.86 (Book Value of Equity 278.7m / Total Liabilities 47.6m) |
| Altman-Z'' = 4.66 = AA |
As of July 08, 2026, the stock is trading at USD 22.22 with a total of 1,447,584 shares traded. Over the past week, the price has changed by -6.64%, over one month by -15.06%, over three months by -30.50% and over the past year by +124.44%.
Current recommended Stop Loss: 20.30 (which is 8.6% or 1 ATR below the current price).
Capricor Therapeutics has received a consensus analysts rating of 4.63. Therefore, it is recommended to buy CAPR.
- StrongBuy: 5
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 53.6 | 141.2% |
P/E Forward = 78.7402
P/S = 124.4331
P/B = 4.8228
P/EG = 0.3831
Revenue TTM = 0.0 USD
EBIT TTM = -111.5m USD
EBITDA TTM = 893.3m USD
Long Term Debt = 13.9m USD (estimated: total debt 21.1m - short term 7.18m)
Short Term Debt = 7.18m USD (from shortTermDebt, last quarter)
Debt = 35.9m USD (from shortLongTermDebtTotal, last quarter) + Leases 14.8m
Net Debt = -242.7m USD (calculated: Debt 35.9m - CCE 278.6m)
Enterprise Value = 1.06b USD (1.30b + Debt 35.9m - CCE 278.6m)
Interest Coverage Ratio = -36.62 (Ebit TTM -111.5m / Interest Expense TTM 3.05m)
EV/FCF = -9.27x (Enterprise Value 1.06b / FCF TTM -114.0m)
FCF Yield = -10.79% (FCF TTM -114.0m / Enterprise Value 1.06b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 3.24 (Enterprise Value 1.06b / Total Assets 326.3m)
Interest Expense / Debt = 8.48% (Interest Expense 3.05m / Debt 35.9m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -88.1m (EBIT -111.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.42 (Total Current Assets 283.1m / Total Current Liabilities 33.6m)
Debt / Equity = 0.13 (Debt 35.9m / totalStockholderEquity, last quarter 278.7m)
Debt / EBITDA = -0.27 (Net Debt -242.7m / EBITDA 893.3m)
Debt / FCF = 2.13 (negative FCF - burning cash) (Net Debt -242.7m / FCF TTM -114.0m)
Total Stockholder Equity = 193.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -47.74% (Net Income -114.6m / Total Assets 326.3m)
RoE = -59.27% (Net Income TTM -114.6m / Total Stockholder Equity 193.3m)
RoCE = -53.82% (EBIT -111.5m / Capital Employed (Equity 193.3m + L.T.Debt 13.9m))
RoIC = -29.39% (negative operating profit) (NOPAT -88.1m / Invested Capital 299.8m)
WACC = 12.50% (E(1.30b)/V(1.33b) * Re(12.66%) + D(35.9m)/V(1.33b) * Rd(8.48%) * (1-Tc(0.21)))
Discount Rate = 12.66% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 40.37%
[DCF] Fair Price = unknown (Cash Flow -114.0m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -1.32 | # QB: -2
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.59 | Chg30d=-0.99% | Revisions=-38% | Analysts=9
EPS next Quarter (2026-09-30): EPS=0.35 | Chg30d=-26.86% | Revisions=-62% | Analysts=9
EPS current Year (2026-12-31): EPS=-0.22 | Chg30d=+42.29% | Revisions=-22% | GrowthEPS=+90.2% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-0.64 | Chg30d=+15.92% | Revisions=-38% | GrowthEPS=-189.0% | GrowthRev=+3.6%
[Analyst] Revisions Ratio: -54% (up=4, down=17)